Drug intelligence / Profile preview

ERB-257

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

ERB-257 is a small molecule drug that acts as a selective agonist of the estrogen receptor beta (ERβ). It was initially developed by Pfizer and previously by Wyeth. The drug's mechanism of action involves selectively activating the estrogen receptor beta, which is thought to have anti-inflammatory and immunomodulatory effects distinct from those mediated by estrogen receptor alpha. ERB-257 was investigated primarily for its potential in treating sepsis, but development was discontinued after Phase 1 clinical trials[1][2][6].

Targets

ESR2 (ERβ)

Beyond the preview

Go deeper on ERB-257.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERB-257.

Explore the full profile